Stableford Capital II LLC Reduces Stock Position in Abbott Laboratories $ABT

Stableford Capital II LLC decreased its position in shares of Abbott Laboratories (NYSE:ABT) by 54.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,098 shares of the healthcare product maker’s stock after selling 7,343 shares during the quarter. Stableford Capital II LLC’s holdings in Abbott Laboratories were worth $553,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. MidAtlantic Capital Management Inc. acquired a new position in shares of Abbott Laboratories during the 4th quarter worth $25,000. Cornerstone Financial Management LLC acquired a new stake in Abbott Laboratories in the 4th quarter valued at about $25,000. Purpose Unlimited Inc. purchased a new position in Abbott Laboratories during the 4th quarter valued at about $25,000. Portfolio Resources Advisor Group Inc. purchased a new position in Abbott Laboratories during the 4th quarter valued at about $26,000. Finally, Abound Financial LLC acquired a new position in Abbott Laboratories during the fourth quarter worth about $26,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Stock Down 1.4%

ABT opened at $105.58 on Wednesday. The stock has a market capitalization of $182.69 billion, a price-to-earnings ratio of 34.17, a price-to-earnings-growth ratio of 2.07 and a beta of 0.59. Abbott Laboratories has a 12 month low of $81.97 and a 12 month high of $137.49. The company has a debt-to-equity ratio of 0.57, a current ratio of 1.38 and a quick ratio of 0.97. The business has a 50-day moving average of $94.23 and a two-hundred day moving average of $100.20.

Abbott Laboratories (NYSE:ABT) last released its earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.28 by $0.03. The firm had revenue of $12.59 billion during the quarter, compared to the consensus estimate of $12.52 billion. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. Abbott Laboratories’s revenue was up 13.0% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.26 earnings per share. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, research analysts expect that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, August 17th. Shareholders of record on Wednesday, July 15th will be given a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend is Wednesday, July 15th. Abbott Laboratories’s payout ratio is 81.55%.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. Mizuho lowered their price target on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research report on Friday, April 17th. Benchmark dropped their price target on Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research report on Friday, April 17th. Evercore reduced their price objective on Abbott Laboratories from $134.00 to $120.00 and set an “outperform” rating on the stock in a research report on Friday, April 17th. Sanford C. Bernstein cut their target price on shares of Abbott Laboratories from $125.00 to $110.00 and set an “outperform” rating for the company in a research note on Friday, April 17th. Finally, Stifel Nicolaus lowered their price target on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a report on Friday, April 17th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $118.17.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.